JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated

Amitabh Das1, Jin Choul Chai2, Kyoung Hwa Jung2

  • 1Department of Bionanotechnology, Hanyang University, Seoul 133-791, Republic of Korea.

Experimental Cell Research
|September 7, 2014
PubMed

Insights

Reducing JMJD2A levels in neuroectodermal stem cells impacts cell cycle and inflammatory genes. This epigenetic modifier affects tumor suppressor genes and may offer a therapeutic target for cancer.

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Neuroscience

Background:

  • Lysine trimethyl-specific histone demethylase JMJD2A is highly expressed in various tumors, but its role in tumor progression is unclear.
  • Understanding JMJD2A's function in p53-null neuroectodermal stem cells (p53(-/-) NE-4Cs) is crucial for elucidating its oncogenic potential.

Purpose of the Study:

  • To identify JMJD2A-regulated genes in p53(-/-) NE-4Cs.
  • To investigate the function of JMJD2A in the context of inflammation and tumor progression.
  • To explore JMJD2A as a potential therapeutic target.

Main Methods:

  • Global gene expression profiling in JMJD2A knockdown (kd) p53(-/-) NE-4Cs, with and without LPS stimulation.
  • Analysis of JMJD2A's effect on primary neural stem cells (NSCs) treated with a p53 inhibitor.
  • Transcription factor motif analysis and molecular network construction using IPA.

Main Results:

  • JMJD2A knockdown significantly down-regulated genes involved in cell cycle, proliferation, and inflammatory responses (e.g., Cdca2, Ccnd2, Stat3).
  • Tumor suppressor genes (e.g., Dapk3, Timp2) were significantly up-regulated upon JMJD2A attenuation.
  • JMJD2A knockdown also affected gene expression in primary NSCs, identifying novel TF binding motifs.

Conclusions:

  • JMJD2A plays a significant role in regulating genes associated with cell cycle, proliferation, and inflammation in neuroectodermal stem cells.
  • The epigenetic modifier JMJD2A influences tumor suppressor gene expression.
  • These findings highlight JMJD2A as a potential therapeutic target for cancers involving neuroectodermal stem cells.